GU Cast | Urology Podcast
A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care.
We chat with study chair Dr Deepak Kilari (Medical College of Wisconsin) and Dr Rana McKay (University of California San Diego), and learn all about the rationale for ASPIRE, the study design, and the novel genomic stratification factors.
Your usual hosts are Renu Eapen and (chemo-sceptic) Declan Murphy!
This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals.
Links:
Alliance website with study details
Urology Times coverage
Clinical Trials registration
